Navigation Links
ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
Date:8/30/2007

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- ConforMIS, a privately held medical device company dedicated to developing and marketing patient-specific orthopedic implants, today announced completion of its move to a new 15,000-sq.-foot headquarter facility in Burlington, MA.

The new facility was chosen to accommodate ConforMIS' rapid growth and marks the completion of the management team's efforts to move commercial operations to Massachusetts. The Burlington headquarter office combines operational functions that previously resided in Foster City, CA and Lexington, MA, including customer service, imaging services, and implant design. The facility will also allow ConforMIS to bring additional capabilities online in one location, such as manufacturing, rapid prototyping, product sterilization, packaging and shipping, and implant engineering and development.

"Our new headquarters will allow us to scale our operations to better support the rapid growth we have experienced over the last year and expect to see over the foreseeable future," said Patrick Hess, CEO of ConforMIS. "Not only will it accommodate the ongoing expansion of key company functions, it also gives us the ability to bring in new infrastructure that was not possible at our previous facilities."

The new offices are located at 2 Fourth Avenue, Burlington, MA 01803. The company's telephone numbers, including those for Imaging Services and Customer Service, remain the same.

About ConforMIS, Inc.

ConforMIS is a privately held medical device company whose mission is to provide best-in-class, minimally invasive implants for orthopedics and sports medicine through the use of its proprietary iFit Technology(TM). The iFit Technology is a patent-protected, software-enabled process for converting CT and MR imaging data into personalized, patient-specific implants. This "image-to-implant" technology allows for precisely sized and shaped implants that reduce or eliminate the need for cartilage or bone resection and radically simplify the surgical procedure. To date, the company has applied this technology to the knee joint and developed a comprehensive line of knee implants for all stages of osteoarthritis. For more information please visit http://www.conformis.com.

Contact:

Patrick Hess, CEO

(650) 286-4151 ext. 1102

Jong Lee, SVP Marketing

(781) 860-5111 ext. 1107

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE ConforMIS, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin spaceport committee moves closer to formation
2. Sonic Foundrys Mediasite moves to podcasts
3. Blogging moves to corporate America
4. A budget that moves Wisconsin forward
5. Merge eFilm corporate merger with Canadian firm moves ahead
6. Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters
7. Rayovac to Relocate Headquarters
8. RedPrairie Establishes Asia-Pacific Headquarters in Shanghai
9. Data centers: Buyers beware of over-hyped facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of ... reported its financial results for the fourth quarter and full ... 4Q16 record quarterly net sales of $1.13 billion, ... 4Q16 EMEA-APAC segment net sales ... Americas net sales increased 2.5%, or down 0.9% on an ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):